메뉴 건너뛰기




Volumn 5, Issue 5, 2005, Pages 605-615

Challenges and opportunities: What we are learning from the clinical natalizumab experience

Author keywords

interferons; Clinical trials; Glatiramer acetate; JC virus; Mitoxantrone; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Therapeutic monoclonal antibodies

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; VERY LATE ACTIVATION ANTIGEN 4;

EID: 26444560501     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.5.605     Document Type: Review
Times cited : (7)

References (50)
  • 1
    • 0037154192 scopus 로고    scopus 로고
    • Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
    • Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178 (2002).
    • (2002) Neurology , vol.58 , pp. 169-178
    • Goodin, D.S.1    Frohman, E.M.2    Garmany, G.P.3
  • 2
    • 22844445587 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
    • Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , pp. 362-368
    • Van Assche, G.1    Van Ranst, M.2    Sciot, R.3
  • 5
    • 22844438117 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences
    • Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N. Engl. J. Med 353, 414-416 (2005).
    • (2005) N. Engl. J. Med , vol.353 , pp. 414-416
    • Berger, J.R.1    Koralnik, I.J.2
  • 6
    • 0037029424 scopus 로고    scopus 로고
    • Multiple sclerosis
    • Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). Excellent review of the immunopathology of multiple sclerosis.
    • (2002) Lancet , vol.359 , pp. 1221-1231
    • Compston, A.1    Coles, A.2
  • 7
    • 0036788406 scopus 로고    scopus 로고
    • Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
    • Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202-2212 (2002).
    • (2002) Brain , vol.125 , pp. 2202-2212
    • Kuhlmann, T.1    Lingfeld, G.2    Bitsch, A.3    Schuchardt, J.4    Bruck, W.5
  • 8
    • 16844364980 scopus 로고    scopus 로고
    • Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology
    • Geurts JJ, Bo L, Pouwels PJ et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am. J. Neuroradiol. 26, 572-577 (2005).
    • (2005) Am. J. Neuroradiol. , vol.26 , pp. 572-577
    • Geurts, J.J.1    Bo, L.2    Pouwels, P.J.3
  • 10
    • 2442532533 scopus 로고    scopus 로고
    • How the brain repairs itself: New therapeutic strategies in inflammatory and degenerative CNS disorders
    • Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol. 3(6), 372-378 (2004). Controversial and important contribution to the field of neuroprotection and immunomodulation in repair and regeneration.
    • (2004) Lancet Neurol. , vol.3 , Issue.6 , pp. 372-378
    • Martino, G.1
  • 11
    • 23944444890 scopus 로고    scopus 로고
    • IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
    • Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 1-5 (2005).
    • (2005) J. Exp. Med. , vol.202 , pp. 1-5
    • Lennon, V.A.1    Kryzer, T.J.2    Pittock, S.J.3    Verkman, A.S.4    Hinson, S.R.5
  • 12
    • 1342345214 scopus 로고    scopus 로고
    • The CD4-Th1 model for multiple sclerosis: A crucial re-appraisal
    • Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol. 25, 132-137 (2004).
    • (2004) Trends Immunol. , vol.25 , pp. 132-137
    • Lassmann, H.1    Ransohoff, R.M.2
  • 13
    • 0342906187 scopus 로고    scopus 로고
    • Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
    • Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6), 707-177 (2000).
    • (2000) Ann. Neurol. , vol.47 , Issue.6 , pp. 707-1177
    • Lucchinetti, C.1    Bruck, W.2    Parisi, J.3
  • 14
    • 17644398787 scopus 로고    scopus 로고
    • Anti{a}4 integrin therapy for multiple sclerosis: Mechanisms and rationale
    • Rice GPA, Hartung HP, Calabresi PA. Anti{a}4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336-1342 (2005). Review of the mechanistic studies of very late antigen (VLA)-4 blockade in disease.
    • (2005) Neurology , vol.64 , pp. 1336-1342
    • Rice, G.P.A.1    Hartung, H.P.2    Calabresi, P.A.3
  • 15
    • 20844454381 scopus 로고    scopus 로고
    • Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab
    • Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Rev. Drug Discov. 4, 510-518 (2005).
    • (2005) Nature Rev. Drug Discov. , vol.4 , pp. 510-518
    • Steinman, L.1
  • 16
    • 3042739652 scopus 로고    scopus 로고
    • Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS
    • Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. 4, 571-580 (2004).
    • (2004) Expert Rev. Neurother. , vol.4 , pp. 571-580
    • Rudick, R.A.1    Sandrock, A.2
  • 17
    • 0344496250 scopus 로고    scopus 로고
    • Novel approaches to treating inflammatory bowel disease: Targeting α4 integrin
    • Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting α4 integrin. Am. J. Gastroenterol. 98(11), 2372-2382 (2003).
    • (2003) Am. J. Gastroenterol. , vol.98 , Issue.11 , pp. 2372-2382
    • Sandborn, W.J.1    Yednock, T.A.2
  • 18
    • 0034123924 scopus 로고    scopus 로고
    • Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment
    • Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123, 1092-1101 (2000).
    • (2000) Brain , vol.123 , pp. 1092-1101
    • Carrithers, M.D.1    Visintin, I.2    Kang, S.J.3    Janeway Jr., C.A.4
  • 19
    • 0037413467 scopus 로고    scopus 로고
    • A controlled trial of natalizumab for relapsing multiple sclerosis
    • Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , pp. 15-23
    • Miller, D.H.1    Khan, O.A.2    Sheremata, W.A.3
  • 25
    • 0035003051 scopus 로고    scopus 로고
    • Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
    • Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49, 677-681 (2001).
    • (2001) Ann. Neurol. , vol.49 , pp. 677-681
    • Lublin, F.D.1    Reingold, S.C.2
  • 26
    • 0142122890 scopus 로고    scopus 로고
    • Scientific and ethical issues in the use of placebo and active controls in clinical trials
    • Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J. Bone Miner. Res. 18, 1121 (2003).
    • (2003) J. Bone Miner. Res. , vol.18 , pp. 1121
    • Ellenberg, S.S.1
  • 27
    • 0035922438 scopus 로고    scopus 로고
    • The ethics of placebo-controlled trials - A middle ground
    • Emanuel EJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. N. Engl. J. Med. 345, 915-918 (2001).
    • (2001) N. Engl. J. Med. , vol.345 , pp. 915-918
    • Emanuel, E.J.1    Miller, F.G.2
  • 28
    • 4143062563 scopus 로고    scopus 로고
    • Oversight of human participants research: Identifying problems to evaluate reform proposals
    • Emanuel EJ, Wood A, Fleischman A et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann. Intern. Med. 141, 282-291 (2004). Reviews and provides important context for the issues surrounding clinical trial design using placebo.
    • (2004) Ann. Intern. Med. , vol.141 , pp. 282-291
    • Emanuel, E.J.1    Wood, A.2    Fleischman, A.3
  • 29
    • 22544448947 scopus 로고    scopus 로고
    • Obstacles and opportunities in translational research
    • Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nature Med. 11, 705 (2005).
    • (2005) Nature Med. , vol.11 , pp. 705
    • Horig, H.1    Marincola, E.2    Marincola, F.M.3
  • 30
    • 0035849993 scopus 로고    scopus 로고
    • Research involving human subjects in developing countries
    • Koski G, Nightingale SL. Research involving human subjects in developing countries. N. Engl. J. Med. 342 (2001).
    • (2001) N. Engl. J. Med. , pp. 342
    • Koski, G.1    Nightingale, S.L.2
  • 31
    • 0037070795 scopus 로고    scopus 로고
    • Placebo-controlled trials and the Declaration of Helsinki
    • Lewis JA, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet 359, 1337-40 (2002).
    • (2002) Lancet , vol.359 , pp. 1337-1340
    • Lewis, J.A.1    Kreutz, G.2    Sampaio, C.3    Van Zwieten-Boot, B.4
  • 32
    • 0035003051 scopus 로고    scopus 로고
    • Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
    • Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49(5), 677-681 (2001).
    • (2001) Ann. Neurol. , vol.49 , Issue.5 , pp. 677-681
    • Lublin, F.D.1    Reingold, S.C.2
  • 33
    • 0036946212 scopus 로고    scopus 로고
    • Clinical trials at AHCs: The perspective of an academic clinical trials office
    • Paller MS, Hostetler L, Dykhuis DA. Clinical trials at AHCs: The perspective of an academic clinical trials office. Acad. Med. 77, 1201-1206 (2000).
    • (2000) Acad. Med. , vol.77 , pp. 1201-1206
    • Paller, M.S.1    Hostetler, L.2    Dykhuis, D.A.3
  • 34
    • 0034687109 scopus 로고    scopus 로고
    • The ethics of placebo-controlled trials
    • Reynolds T. The ethics of placebo-controlled trials. Ann. Intern. Med. 133, 491-492 (2000).
    • (2000) Ann. Intern. Med. , vol.133 , pp. 491-492
    • Reynolds, T.1
  • 35
    • 0035849989 scopus 로고    scopus 로고
    • Ethical issues in the design and conduct of clinical trials in developing countries
    • Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N. Engl. J. Med. 345 (2001).
    • (2001) N. Engl. J. Med. , pp. 345
    • Shapiro, H.T.1    Meslin, E.M.2
  • 36
    • 0142091166 scopus 로고    scopus 로고
    • The ethics of placebo-controlled trials
    • Weijer C. The ethics of placebo-controlled trials. J. Bone Miner. Res. 18, 1150-1153 (2003).
    • (2003) J. Bone Miner. Res. , vol.18 , pp. 1150-1153
    • Weijer, C.1
  • 37
    • 0031744008 scopus 로고    scopus 로고
    • The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis
    • Noseworthy JH, O'Brien P, Erickson BJ et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51, 1342-1352 (1998).
    • (1998) Neurology , vol.51 , pp. 1342-1352
    • Noseworthy, J.H.1    O'Brien, P.2    Erickson, B.J.3
  • 39
    • 0035052096 scopus 로고    scopus 로고
    • Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis
    • Theien BE, Vanderlugt CL, Eagar TN et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995-1006 (2001).
    • (2001) J. Clin. Invest. , vol.107 , pp. 995-1006
    • Theien, B.E.1    Vanderlugt, C.L.2    Eagar, T.N.3
  • 40
    • 0344305462 scopus 로고    scopus 로고
    • Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE
    • Theien BE, Vanderlugt CL, Nickerson-Nutter C et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102, 4464-4471 (2003).
    • (2003) Blood , vol.102 , pp. 4464-4471
    • Theien, B.E.1    Vanderlugt, C.L.2    Nickerson-Nutter, C.3
  • 41
    • 0037097524 scopus 로고    scopus 로고
    • JC virus load in progressive multifocal leukoencephalopathy: Analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions
    • Garcia De Viedma D, Diaz Infantes M, Miralles P et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin. Infect. Dis. 34, 1568-1575 (2002).
    • (2002) Clin. Infect. Dis. , vol.34 , pp. 1568-1575
    • Garcia De Viedma, D.1    Diaz Infantes, M.2    Miralles, P.3
  • 42
    • 11144239958 scopus 로고    scopus 로고
    • Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection
    • Henmi C, Sawa H, Iwata H Orba Y, Tanaka S, Nagashima K. Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection. Biochem. Biophys. Res. Commun. 327, 242-251 (2005).
    • (2005) Biochem. Biophys. Res. Commun. , vol.327 , pp. 242-251
    • Henmi, C.1    Sawa, H.2    Iwata, H.3    Orba, Y.4    Tanaka, S.5    Nagashima, K.6
  • 43
    • 0037374763 scopus 로고    scopus 로고
    • α4β1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level
    • Caruso M, Belloni L, Sthandier O, Amati P, Garcia MI. α4β1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J. Virol. 77, 3913-3921 (2003).
    • (2003) J. Virol. , vol.77 , pp. 3913-3921
    • Caruso, M.1    Belloni, L.2    Sthandier, O.3    Amati, P.4    Garcia, M.I.5
  • 44
    • 16644393095 scopus 로고    scopus 로고
    • The JC virus-like particle overlay assay
    • Sawa H, Komagome R. The JC virus-like particle overlay assay. Methods Mol. Biol. 292, 175-86 (2005).
    • (2005) Methods Mol. Biol. , vol.292 , pp. 175-186
    • Sawa, H.1    Komagome, R.2
  • 45
    • 2642572579 scopus 로고    scopus 로고
    • New insights into progressive multifocal leukoencephalopathy
    • Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 376-370 (2004).
    • (2004) Curr. Opin. Neurol. , vol.17 , pp. 376-1370
    • Koralnik, I.J.1
  • 46
    • 0034103105 scopus 로고    scopus 로고
    • The HHV6 paradox: Ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach
    • Blumberg BM, Mock DJ, Powers JM et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J. Clin. Virol. 16, 159-178 (2000).
    • (2000) J. Clin. Virol. , vol.16 , pp. 159-178
    • Blumberg, B.M.1    Mock, D.J.2    Powers, J.M.3
  • 48
    • 4444294103 scopus 로고    scopus 로고
    • Increased CXCL8 (IL-8) expression in multiple sclerosis
    • Lund BT, Ashikian N, Ta HQ et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 155, 161-171 (2004).
    • (2004) J. Neuroimmunol. , vol.155 , pp. 161-171
    • Lund, B.T.1    Ashikian, N.2    Ta, H.Q.3
  • 49
    • 19944427487 scopus 로고    scopus 로고
    • Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories
    • Rollison DE, Utaipat U, Ryschkewitsch C et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int. J. Cancer 113, 769-774 (2005).
    • (2005) Int. J. Cancer , vol.113 , pp. 769-774
    • Rollison, D.E.1    Utaipat, U.2    Ryschkewitsch, C.3
  • 50


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.